Diabetic foot ulcers (DFUs) are one the common complications of diabetes mellitus. Many
trials were performed to evaluate the effect of recombinant human epidermal growth factor …

Diabetic foot ulceration is a major complication of diabetes mellitus. Recombinant human
epidermal growth factor (rhEGF) is used topically in the treatment of diabetic foot ulcers. This …

To evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF)
in treating diabetic foot ulcers (DFUs), we conducted both database searches (PubMed …

Diabetic foot ulcer and its complications are becoming more and more serious problems
threatening people's health. In the last decade, multiple growth factors and their combined …

Aims This study was conducted to evaluate the efficacy and safety of a novel spray-applied
growth factor therapy containing recombinant human epidermal growth factor (rhEGF) for the …

Introduction This study examined the relative efficacy of growth factor therapies in healing
diabetes‐related foot ulcers (DFU). Methods PubMed and Cochrane databases were …

Background After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

The healing process in diabetic foot ulcer (DFU) is hindered by factors such as chronic
inflammation, defects in fibroblast function, poor angiogenesis, and lack of cell migration …

Background: Peripheral neuropathy, vascular disease and immune dysfunction contribute
towards the pathogenesis of the diabetic foot. Given that the only growth factor approved by …

Background. Recombinant proteins and growth factors are emerging therapies for diabetic
foot ulcers. Despite several clinical reports, there has been no comprehensive and …